SW-682 i avancerede solide tumorer
En fase 1a/1b dosiseskalering, dosisudvidelsesundersøgelse af SW-682 hos deltagere med avancerede solide tumorer beriget for dem med mutationer i flodhestvejen
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: US Medical Information
- Telefonnummer: 888-275-7376
- E-mail: eMediUSA@emdserono.com
Studiesteder
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85258
- Rekruttering
- HonorHealth Research Institute
-
Ledende efterforsker:
- Muhammad R Khawaja, MD
-
Kontakt:
- E-mail: mkhawaja@honorhealth.com
-
-
California
-
Los Angeles, California, Forenede Stater, 90033
- Rekruttering
- USC Norris Comprehensive Cancer Center and Hospital
-
Ledende efterforsker:
- Diana Hanna, MD
-
Kontakt:
- E-mail: diana.hanna@med.usc.edu
-
Sacramento, California, Forenede Stater, 92093
- Rekruttering
- UC San Diego Moores Cancer Center
-
Ledende efterforsker:
- Sandip Patel, MD
-
Kontakt:
- E-mail: sandippatel@ucsd.edu
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- UCLA Hematology-Oncology - Santa Monica
-
Ledende efterforsker:
- Arun S Singh, MD
-
Kontakt:
- E-mail: Asingh@mednet.ucla.edu
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44106
- Rekruttering
- University Hospital of Cleveland
-
Ledende efterforsker:
- Afshin Dowlati, MD
-
Kontakt:
- Telefonnummer: 216-844-3951
- E-mail: afshin.dowlati@uhhospitals.org
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- Oregon Health and Science University, Knight Cancer Institute - Marquam Hill
-
Ledende efterforsker:
- Shivaani Kummar
-
Kontakt:
- E-mail: kummar@ohsu.edu
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230
- Rekruttering
- Mary Crowley Research Center US Oncology
-
Ledende efterforsker:
- Douglas Orr, MD
-
Kontakt:
- Telefonnummer: 972-566-3000
- E-mail: Douglas.Orr@scri.com
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- U.T. MD Anderson Cancer Center
-
Ledende efterforsker:
- Timothy Yap, MD
-
Kontakt:
- E-mail: TYap@mdanderson.org
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
Histologically confirmed, metastatic, or unresectable solid cancer that has either not responded to or progressed during or after appropriate prior systemic anticancer therapy including chemotherapy, immunotherapy, radiation therapy, or appropriate targeted therapy, or for which there is no treatment available or prior SOC therapy was not tolerated and for which there is no further SOC treatment available
-
Part 1: must have one of the following:
- Mesothelioma with or without NF2 mutations
- Advanced solid tumors with NF2 mutations
- Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE).
-
Part 2: must have the tumor histology and oncogenic mutation or genomic aberration specific to each dose expansion cohort defined below:
- Cohort 1: Participants with mesothelioma with or without NF2 mutations
- Cohort 2: Participants with advanced solid tumors with NF2 mutations
- Cohort 3: Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation
- Cohort 4: SW-682 with appropriate combination therapy.
-
In both parts, participants should have known oncogenic mutation identified by Next Generation Sequencing or local assay
-
Must have archival tumor tissue or agree to a fresh tumor biopsy at screening
-
Measurable disease per RECIST 1.1
-
Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
-
Adequate bone marrow, kidney, hepatic, and coagulation function
Key Exclusion Criteria:
- Evidence of symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression
- Clinically significant cardiac disease or abnormal cardiac parameters
- Preexistence or inheritance of a familial renal syndrome
- Concomitant non-anti-arrhythmic medications that are known to prolong the QTc interval
- Concomitant medicines that are known strong/moderate inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and/or CYP1A2 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of CYP3A4, CYP2C19, CYP2D6, CYP1A2, and/or CYP2B6 within 14 days or 5 half-lives before the first dose of study treatment
- Concomitant medicines that are known sensitive substrates of PGP, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT2
- Clinically significant active infection (bacterial, fungal, or viral)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Phase 1 Dose Escalation Cohorts Ranging in Dose
Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort. |
SW-682 tablet administered orally |
|
Eksperimentel: Part 2 Dose Expansion Cohort 1
Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Eksperimentel: Part 2 Dose Expansion Cohort 2
Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Eksperimentel: Part 2 Dose Expansion Cohort 3
Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data. |
SW-682 tablet administered orally |
|
Eksperimentel: Part 2 Dose Expansion Cohort 4
Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data. |
SW-682 tablet administered orally Appropriate combination therapy |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Adverse Events (Part 1 Only)
Tidsramme: Up to 24 months
|
Safety and tolerability endpoint evaluation via incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment emergent adverse events (TEAE) |
Up to 24 months
|
|
Maximum Tolerated Dose (Part 1 Only)
Tidsramme: Up to 24 months
|
The maximum tolerated dose (MTD) for SW-682, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1. |
Up to 24 months
|
|
Recommended Dose for Expansion (Part 1 Only)
Tidsramme: Up to 24 months
|
The recommended dose for expansion (RDE) will be determined based on all safety, tolerability, pharmacokinetics (PK), preliminary antitumor efficacy, and other available data from Part 1 of the study. |
Up to 24 months
|
|
Objective Response Rate (Part 2 Only)
Tidsramme: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in plasma and urine concentrations of SW-682
Tidsramme: Up to 24 months
|
Plasma and urine concentrations of SW-682 and any relevant metabolite(s) will be measured to evaluate systemic exposures and renal elimination. |
Up to 24 months
|
|
Objective Response Rate (Part 1 Only)
Tidsramme: Up to 24 months
|
Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator. |
Up to 24 months
|
|
Disease Control Rate
Tidsramme: Up to 24 months
|
Disease control rate (DCR), defined as the percentage of participants with CR, PR, or stable disease (SD) after starting study treatment. |
Up to 24 months
|
|
Duration of Response
Tidsramme: Up to 24 months
|
Duration of response (DoR), defined as the time from response (CR + PR using RECIST v1.1, mRECIST and/or (GCIG) criteria for CA-125 response in ovarian cancer, as applicable) to disease progression and/or death, whichever occurs first. |
Up to 24 months
|
|
Progression-Free Survival
Tidsramme: Up to 24 months
|
Progression-free survival (PFS), defined as the time from the date of the first administration of study treatment to the first documented disease progression per RECIST v1.1, mRECIST, and/or GCIG CA-125, as applicable, or death due to any cause, whichever occurs first. |
Up to 24 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Medical Responsible, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Lungesygdomme
- Neoplasmer, kirtel og epitel
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Adenom
- Neoplasmer, mesotheliale
- Pleurale neoplasmer
- Mesotheliom
- Mesotheliom, ondartet
- Terapeutik
- Kombineret modalitetsterapi
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- TEAD-AST-101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .